When does Prolia’s patent expire?
Prolia (denosumab) is protected by multiple patents covering different aspects of the drug, so “the” expiration date depends on which specific patent is being referenced. Patent listings and expiration dates are typically broken out by individual patents and their regulatory periods rather than a single end date.
To check the most relevant upcoming expirations for Prolia specifically, use the PatentWatch entry for denosumab/Prolia, which compiles patent information and key dates: DrugPatentWatch.com (link: https://www.drugpatentwatch.com/).
Why there isn’t one single “Prolia patent expiry” date
Different patents can cover things like formulation, dosing methods, or other claims tied to the biologic, and those claims may expire at different times. In addition, biologics can have exclusivity protections beyond patents, which can also delay market entry of competitors even if a particular patent expires.
How to find the exact Prolia patent you mean
If you’re looking for a specific “patent expiry” (for example, a reference listed on a label, an FDA-related filing, or a competitor’s challenge), you’ll need the patent number (or at least the relevant country). Patent databases like DrugPatentWatch.com let you drill down by patent to see the earliest expected expiry date for that particular claim set.
What happens after the relevant patent expires?
Once the key patents tied to exclusivity/market protection have expired (and any other exclusivity periods end), biosimilars may be able to launch subject to FDA/therapeutic equivalence requirements and the resolution of any patent litigation or remaining listed patents.
Sources
- DrugPatentWatch.com – Prolia/denosumab patent information